Q Investor Presentation
|
|
- Ami Hancock
- 5 years ago
- Views:
Transcription
1 Global Leaders in Sleep and Respiratory Medicine Q Investor Presentation 1
2 Forward Looking Statements Statements contained in this release that are not historical facts are forward-looking statements as contemplated by the Private Securities Litigation Reform Act of 1995.These forward-looking statements, including statements regarding the Company s future revenue, earnings or expenses, new product development, and new markets for the Company's products are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward looking statements. Additional risks and uncertainties are discussed in the Company's Annual Report on Form 10- K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission. Those reports are available on the Company's Web site. 2
3 Global Leader in SDB and Respiratory Medicine Global leading developer, manufacturer and distributor of medical devices to treat sleep-disordered breathing and other respiratory conditions. 3
4 What We Do Improve quality of life for people with sleep-disordered breathing or respiratory failure through: Innovative products and technology Raise the benchmark for effective diagnosis, therapy, patient comfort and compliance. Education, awareness, screening Help the medical community and public to understand sleep-disordered breathing. Provide tools to identify people at risk. Ventilation solutions Provide temporary or long-term ventilatory assistance. Monitoring systems Ensure therapy meets clinical requirements. 4
5 Market Opportunities Market Size 20% sleep apnea in the adult population. 13% Mild; 7% Moderate to Severe 7% 13% 2002 Young T, Peppard E, and Gottlieb D. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002; 165:
6 What is Sleep-Disordered Breathing? Abnormal respiration during sleep (e.g. snoring, apneas, reduced airflow). Most prevalent is obstructive sleep apnea a collapse of the upper airway despite ongoing breathing efforts. Other types include central sleep apnea characterized by the lack of breathing effort and mixed apneas (combination of obstructive and central sleep apnea). Healthy upper airway Partially obstructed upper airway Obstructed upper airway 6
7 Visible and Hidden Impacts of Sleep-Disordered Breathing SDB Externally Choking arousals Fragmented sleep Nocturia Unrefreshed on wakening Morning headaches Impaired concentration Daytime sleepiness Internally Hypoxemia Hypercapnia Sympathetic activation Endothelial dysfunction Metabolic dysregulation Hypertension Arrhythmias Myocardial infarction Stroke 7
8 Sleep Apnea is Prevalent in Patients with Other Serious Conditions Drug-Resistant Hypertension 83% Logan et al. J. Hypertension 2001 Obesity Congestive Heart Failure Type 2 Diabetes 72% 77% 76% O Keefe and Patterson. Obes Surgery 2004 Oldenburg et al, Eur J Heart Failure, 2007 Einhorn et al. Endocrine Prac 2007 Pacemakers Acute Coronary Syndrome 59% 57% Garrigue et al. Circulation 2007 Yumino et al. Am J Cardiology 2007 Atrial Fibrillation 49% Gami et al. Circulation 2004 All Hypertension 37% Sjostrom et al. Thorax 2002 Coronary Artery Disease 30% Schafer et al. Cardiology 1999 * Apnea-Hypopnea Index 5 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 8
9 Links Between OSA and Chronic Disease FIGURE Possible mechanistic links between obstructive sleep apnea, obesity, metabolic syndrome, and type 2 diabetes Obstructive Sleep Apnea Intermittent Hypoxia Oxidative Stress Sleep Fragmentation / Sleep Deprivation Neurohormonal Changes Type 2 Diabetes Obesity Insulin Resistance Inflammation Hypertension Dyslipidemia Metabolic Syndrome Reproduced with permission from Tasali E, p MSM, Obstructive sleep apnea and metabolic syndrome: Alterations in glucose metabolism and inflammation. Proc AM Thorax Soc. 5: (2008). Official journal of the American Thoracic Society. Copyright American Thoracic Society. 9
10 Our Five Strategic Initiatives 1. Sleep-disordered breathing (SDB) and its association with and impact on cardiovascular and cerebrovascular diseases. 2. SDB and its association with and impact on type 2 diabetes mellitus. 3. SDB and its association with and impact on perioperative risk. 4. SDB and its association with and impact on occupational health and safety. 5. Ventilatory support for respiratory failure due to chronic obstructive pulmonary disease (overlap syndrome) and neuromuscular diseases. 10
11 Our Commitment to Ventilation Developing innovative and effective mechanical ventilation solutions to improve the quality of life for patients and providing assistance to care-givers. We provide: Mechanical ventilation for congenital defects, illness, trauma, obesity, cardiac arrest, neuromuscular disease, pulmonary disease and sometimes sepsis and shock. Non-invasive ventilation solutions with the best-in-class leak algorithms to support temporary or long-term ventilation. Invasive ventilation solutions for dependant patients with value or leak ventilators providing both pressure and volume ventilation. 11
12 Acquisitions / Partnerships Grundler home / hospital humidification. BiancaMed for RVI; non-contact SDB device (radio frequency / Doppler technology). Carefusion 5 year exclusive for US ventilation; NIV is largest and fastest-growing segment in US subacute market. 12
13 OSA and Cardiovascular Disease 13
14 Why Sleep Apnea and Cardiovascular Disease? 1 Logan et al. J. Hypertension 2001; Schafer et al. Cardiology Gottlieb et al, Circulation July Hypertension: Journal of the American Heart Association July Becker et al. Circulation Kaneko et al. NEJM 2003, Maisel et al. UCSD VA Hospital Case Study Data (2002), Teschler et al. AJRCCM 2001 Sleep apnea is highly prevalent in cardiovascular disease patients 1. 30% to 80% of patients for common CVD states. Obstructive sleep apnea increases risk of incident heart failure 2. Men ages with AHI >30 were 68% more likely to develop heart disease than those with AHI <5. Sleep apnea can cause changes in blood vessel function that reduces blood supply to the heart in people who are otherwise healthy 3. Benefits of CPAP treatment: Continuous positive airway pressure treatment reverses blood vessel abnormalities. Sleep apnea therapy lowers blood pressure 4. 4mm Hg to 10mm Hg reduction with CPAP therapy. Sleep apnea therapy improves cardiovascular health 5. Left ventricular ejection fraction, six-minute walk, VO 2 max, afterload, BNP. 14
15 SERVE-HF Clinical Trial Aim: Demonstrate that adaptive servo-ventilation therapy over two years can improve morbidity and mortality in patients with predominant central sleep apnea and heart failure. Design: randomized controlled trial evaluable subjects. Control arm - optimal medical care. Active arm - optimal medical care plus ASV. Status: Actively enrolling in Europe. Progress: Currently enrolled over 800 patients in 60 centers. Main Sub-study: Demonstrate that ASV therapy improves heart failure outcomes such as left ventricular ejection fraction and quality of life metrics (n=300). 15
16 OSA and Diabetes 16
17 Type 2 Diabetes & OSA Clinical Connections 72% of patients with type 2 diabetes suffer from obstructive sleep apnea (OSA) 1. 86% of obese diabetics have OSA. OSA may have a causal role in the development of diabetes 2. OSA is associated with insulin resistance (independent of obesity) 3. Obese patients with sleep apnea are more insulin resistant than patients with simple obesity 4. 30% of patients presenting to a sleep clinic have impaired glucose tolerance or diabetes, of which 40% are undiagnosed 5. 1 Einhorn et al. Endocr Pract Reichmuth et al. Am J Respir Crit Care Med Ip et al Am J Respir Crit Care Med 2002, Punjabi et al. Am J Respir Crit Care Med Tassone et al. Clin Endocrinol Meslier et al. Eur Respir J
18 OSA and Obesity 18
19 Global Obesity Forecast In 2008, 9.8 percent of the world s male population were obese, as were 13.8 percent of women. In 1980, these rates were 4.8 percent and 7.9 percent 1. The World Health Organization predicts there will be 2.3 billion overweight adults in the world by 2015 and more than 700 million of them will be obese. 1 Majid Ezzati, MD et al, of the Imperial College of London 19
20 Peri-operative Risk 20
21 Sleep Apnea Epidemic = Peri-operative Risk More than 60+ million US adults suffer from sleep-disordered breathing 1. More than 85% remain undiagnosed 2. Increase in prevalence of obesity has led to increase in obstructive sleep apnea 3. High prevalence of undiagnosed obstructive sleep apnea in the surgical patient population (24%) 4. 1 Redline et. al Young et al. Sleep Newman et al. Arch Intern Med Chung et al. Anesthesiology
22 Sleep-Disordered Breathing and Occupational Health and Safety 22
23 Transportation Agencies Recognize Link between Sleep-Disordered Breathing and Accidents US UK In October 2009, the National Transportation Safety Board wrote to the US Coast Guard and Federal Motor Carrier Safety Administration recommending screening of all ship pilots, bus and truck drivers for sleep apnea. US Federal Motor Carrier Safety Administration recommended standards for sleep apnea screening in Dec meeting. Truck driver with undiagnosed sleep apnea killed a 26-year old driver. Coroner in the case and father of dead man call for UK professional drivers to be tested. 23
24 Health Plan and Disability Cost Benefits of OSA Treatment Waste Management s Experience 37% reduction in total medical costs for those treated in 1 st year. 79% reduction in short-term disability costs for those treated in 1 st year. 72% reduction in short-term disability days absent in 1 st year. 0% -10% -20% -30% -40% -50% All Medical Costs % Reduction Short-term disability costs Short-term disability absences Short-term disability leaves 52% reduction of employees with a short-term disability leave in 1 st year. -60% -70% Commercial motor vehicle operators with obstructive sleep apnea and treated with positive airway pressure therapy (N=156) Hoffman, et al., Journal of Occupational & Environmental Medicine, vol. 52, no. 5 (2010) -80% -90% -100% 24
25 Health Plan and Disability Cost Benefits of OSA Treatment Schneider Trucking s Experience Results 12 months post-cpap treatment % reduction in total medical expenses = $6,456/year. 91% reduction in hospital admissions. Does not include savings from accidents. Results from original 6-month follow up study. Improved retention by 229%. 73% reduction in accidents. 0% -10% -20% -30% -40% -50% -60% -70% -80% Total Medical Costs % Reduction Hospital Admissions Accidents 1 Berger, et al., CHEST % -100% 25
26 Superior Product Innovation 26
27 New Mask Offerings Considered Best in Class Quattro FX Mirage FX Swift FX The FX Trilogy 27
28 For Her 28
29 PRICE S9 Series Delivers More Comfort, More Compliance, More Connectivity High $ VPAP Adapt Bi-Level Med $ Premium Segment - Elite Low $ Value Segment Escape FEATURES ResMed 2006 Climate control Wireless monitoring Sleep quality indicator Climate control Wireless monitoring Sleep quality indicator Comprehensive data (AHI tracking, mouth leak, central sleep apnea detection) Ultra quiet Easy-Breathe Easy-Breathe waveform makes breathing more comfortable Simple menu settings Seamless integration with optional H5i heated humidifier with Climate Control Simple menu settings Seamless integration with optional H5i heated humidifier with Climate Control Enhanced Vsync technology provides superior patient ventilator synchrony 29
30 Skinit Skins allow a patient to fit the device into their lifestyle. Skins present an opportunity for cash revenue for HMEs. Personalization has been immensely successful across multiple industries. Personalization will lowering the emotional barriers to accepting therapy, which will drive therapy adherence. Therapy adherence drives customer revenue and patient health. Skins create a unique way to reconnect with patients who have abandoned therapy and potentially bring them back in to using a device. 30
31 Stellar 100 Easy Access to Quality Therapy Feature-rich, premium noninvasive ventilator that can also be used invasively. Light, compact and portable. Packed with exciting innovative features. Improved leak management system (VSync), which makes breathing more natural for the patient. 31
32 Financial Results 32
33 68 th Consecutive Quarter of Revenue Growth Q Revenue (Constant Currency) $332.7M +9% (+9%) Net Income $62.9M +8% EPS $ % 33
34 Sales by Region & Product Q Masks & Accessories 46% Flow Generators 54% Americas 55% Europe 36% Asia-Pacific 9% 34
35 US$ '000 Annual Revenue Performance 1,400,000 15% 5YR CAGR 1,200,000 1,000, , , , , YTD 2012 Net revenues 35
36 US$ '000 % of Revenue Net Income Growth 250,000 21% 5YR CAGR 20.0% 200, % 150, , % 14.0% 12.0% 50, % - * YTD % Net Income Net Income as % of Revenue * 2007 Net Income excludes the impact of a voluntary product recall expense of $59.7 million, $41.8 million net of tax. 36
37 Sustained EPS Growth $1.60 $1.40 $1.20 $ % 5YR CAGR $1.44 $1.00 $0.95 $0.80 $0.60 $0.58 $0.69 $0.70 $0.75 $0.40 $0.20 $0.00 * YTD 2012 * 2007 EPS excludes the impact of a voluntary product recall expense of $59.7 million, $41.8 million net of tax. 37
38 Balance Sheet USD '000 Dec-11 Jun-11 Cash/ Marketable Securities 723, ,267 Accounts Receivable 238, ,352 Inventory 184, ,777 Other Current Assets 100,350 82,056 PP&E 441, ,107 Patents/ Goodw ill 322, ,398 Other Assets 30,957 30,965 TOTAL ASSETS 2,041,478 2,068,922 Accounts Payable 45,763 55,194 Accruals 112, ,787 Incom e Taxes Payable 29,814 7,988 Current portion, long term debt 1, Deferred Revenue 57,595 62,362 Long Term Debt 225, ,000 Deferred Incom e Tax 8,495 8,691 TOTAL LIABILITIES 480, ,185 Com m on Stock 834, ,068 Retained Earnings 1,225,252 1,111,862 Treasury Stock -739, ,625 Other Com p Gain (Loss) 240, ,432 STOCKHOLDERS EQUITY 1,561,075 1,730,737 38
39 Global leader in sleep medicine. Committed to increasing education and awareness of sleep-disordered breathing. Complete solutions from screening to support and monitoring. Advancing ventilation for respiratory care. Creating new benchmarks in ventilation to meet the challenges of respiratory care. Innovative homecare solutions to improve quality of life. Trusted track record, poised for greater success. Strong leadership and globally-diversified team of over 3,300 personnel with diverse expertise. Continuous innovation and investment in research and product development. Ongoing journey of growth, leadership and excellence. Strong balance sheet. 39
About VirtuOx. Was marketed exclusively by Phillips Healthcare division, Respironics for 3 years
About VirtuOx VirtuOx, Inc. assists physicians and Durable Medical Equipment (DME)( companies diagnose respiratory diseases and qualify patients for home respiratory equipment under the guidelines of CMS
More informationInvestor Presentation. Q April 26, 2018
Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationApnea-Hypopnea- Index The new old biomarker for Sleep-Disordered Breathing. Alan S Maisel MD
Apnea-Hypopnea- Index The new old biomarker for Sleep-Disordered Breathing Alan S Maisel MD Triumvirate of Health-public awareness 1.8% Sleep Physical Fitness Nutrition 91.3% 99.9% Sleep is important to
More informationInvestor Presentation. Q May 21, 2018
Investor Presentation Q3 2018 May 21, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationInvestor Presentation. Q October 26, 2017
Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
More informationGlobal Leaders in Sleep and Respiratory Medicine. Investor Update Q Peter Farrell, PhD. Chairman & CEO. Q2 Fiscal Year 2007 ResMed
Global Leaders in Sleep and Respiratory Medicine Investor Update Q2 2007 Peter Farrell, PhD Chairman & CEO Q2 Fiscal Year 2007 ResMed 2006 1 Forward-Looking Statements Statements contained in this presentation
More informationDiabetes & Obstructive Sleep Apnoea risk. Jaynie Pateraki MSc RGN
Diabetes & Obstructive Sleep Apnoea risk Jaynie Pateraki MSc RGN Non-REM - REM - Both - Unrelated - Common disorders of Sleep Sleep Walking Night terrors Periodic leg movements Sleep automatism Nightmares
More informationHeart Failure and Sleep Disordered Breathing (SDB) Unhappy Bedfellows
Question Heart Failure and Sleep Disordered Breathing (SDB) Unhappy Bedfellows 1 ResMed 2012 07 2 ResMed 2012 07 Open Airway 3 ResMed 2012 07 Flow Limitation Snore 4 ResMed 2012 07 Apnoea 5 ResMed 2012
More informationSleep Apnea: Vascular and Metabolic Complications
Sleep Apnea: Vascular and Metabolic Complications Vahid Mohsenin, M.D. Professor of Medicine Yale University School of Medicine Director, Yale Center for Sleep Medicine Definitions Apnea: Cessation of
More informationThe International Franco - Palestinian Congress in Sleep Medicine
The International Franco - Palestinian Congress in Sleep Medicine Temporomandibular Disorders and Sleep Apnea 26 and 27 October, 2017 Notre Dame Hotel, Jerusalem The Consequences of Untreated Sleep Apnea
More informationOSA and COPD: What happens when the two OVERLAP?
2011 ISRC Seminar 1 COPD OSA OSA and COPD: What happens when the two OVERLAP? Overlap Syndrome 1 OSA and COPD: What happens when the two OVERLAP? ResMed 10 JAN Global leaders in sleep and respiratory medicine
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationFinancial Presentation
Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with
More information2014 Full Year Results Presentation. Year ended 31 March 2014
2014 Full Year Results Presentation Year ended 31 March 2014 26-30 May 2014 1 Full year result highlights 12 months to 31 March 2014 NZ$M PCP CC 1 Record net profit after tax 97.1 +26% +46% Record operating
More informationFor personal use only
FY2015 Half Year Results Presentation 6 months ended 30 September 2014 24 28 November 2014 1 First half result highlights H1 FY15 (6 months to 30 September 2014) PCP CC 1 Operating profit +8% +64% RAC
More informationFull Year Update FY2011 May 2011
Full Year Update FY2011 May 2011 1 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated US$3.0+ billion and growing market opportunity High level
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationItamar Medical. December Investors Presentation.
Itamar Medical December 2017. Investors Presentation. Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration
More informationHalf Year Update FY2012 November 2011
Half Year Update FY2012 November 2011 1 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated US$3.0+ billion and growing market opportunity High
More informationIn-Patient Sleep Testing/Management Boaz Markewitz, MD
In-Patient Sleep Testing/Management Boaz Markewitz, MD Objectives: Discuss inpatient sleep programs and if they provide a benefit to patients and sleep centers Identify things needed to be considered when
More informationSleep and the Heart Reversing the Effects of Sleep Apnea to Better Manage Heart Disease
1 Sleep and the Heart Reversing the Effects of Sleep Apnea to Better Manage Heart Disease Rami Khayat, MD Professor of Internal Medicine Director, OSU Sleep Heart Program Medical Director, Department of
More informationSleep and the Heart. Physiologic Changes in Cardiovascular Parameters during Sleep
Sleep and the Heart Rami N. Khayat, MD Professor of Internal Medicine Medical Director, Department of Respiratory Therapy Division of Pulmonary, Critical Care and Sleep Medicine The Ohio State University
More informationSleep and the Heart. Rami N. Khayat, MD
Sleep and the Heart Rami N. Khayat, MD Professor of Internal Medicine Medical Director, Department of Respiratory Therapy Division of Pulmonary, Critical Care and Sleep Medicine The Ohio State University
More informationObstructive Sleep Apnea
Obstructive Sleep Apnea Definition: Repetitive episodes of upper airway obstruction (complete or partial) that occur during sleep and are associated with arousals or desaturations +/or daytime sleepiness.
More informationASX Investor Presentation
ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited
More informationFY07 Full Year Update & Overview
FY07 Full Year Update & Overview Investment Highlights Leading player in respiratory humidification systems Consistent growth strategy Estimated US$2+ billion and growing market opportunity High level
More informationInvestment Highlights
FY08 Full Year Update and Overview Investment Highlights Leading player in respiratory humidification systems Consistent growth strategy Estimated US$2.5+ billion and growing market opportunity High level
More informationInvestor Presentation. Q October 25, 2018
Investor Presentation Q1 2019 October 25, 2018 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results
More informationFY06 Full Year Update & Overview
FY06 Full Year Update & Overview Investment Highlights Leading player in heated humidification systems Consistent growth strategy Estimated US$2+ billion and growing market opportunity High level of innovation
More informationWhat is SDB? Obstructive sleep apnea-hypopnea syndrome (OSAHS)
Have a Good Sleep? Estimated 70 million Americans have clinically significant sleep problems Chronic insomnias report decreased quality of life, memory and attention problems, decreased physical health
More informationSleep and the Heart. Sleep Stages. Sleep and the Heart: non REM 8/31/2016
Sleep and the Heart Overview of sleep Hypertension Arrhythmias Ischemic events CHF Pulmonary Hypertension Cardiac Meds and Sleep Sleep Stages Non-REM sleep(75-80%) Stage 1(5%) Stage 2(50%) Stage 3-4*(15-20%)
More informationFisher & Paykel Healthcare
Fisher & Paykel Healthcare Deutsche Bank / Craigs New Zealand Corporate Day 1 Sydney March 2014 Investment Highlights A leader in respiratory and OSA treatment devices Consistent growth strategy Estimated
More informationChronic NIV in heart failure patients: ASV, NIV and CPAP
Chronic NIV in heart failure patients: ASV, NIV and CPAP João C. Winck, Marta Drummond, Miguel Gonçalves and Tiago Pinto Sleep disordered breathing (SDB), including OSA and central sleep apnoea (CSA),
More informationFor personal use only
Fisher & Paykel Healthcare Inspired and world-leading healthcare solutions FY2016 HALF YEAR RESULTS PRESENTATION 6 months ended 30 September 2015 1 First Half Result Highlights H1 FY2016 (6 months to 30
More informationGeneral Outline. General Outline. Pathogenesis of Metabolic Dysfunction in Sleep Apnea: The Role of Sleep Fragmentation and Intermittent Hypoxemia
Pathogenesis of Metabolic in Sleep Apnea: The Role of Sleep Fragmentation and Intermittent Hypoxemia Naresh M. Punjabi, MD, PhD Associate Professor of Medicine and Epidemiology Johns Hopkins University,
More informationFor personal use only
Fisher & Paykel Healthcare Inspired and world-leading healthcare solutions DEUTSCHE BANK CRAIGS NZ COMPANIES DAY Sydney, 8 March 2016 1 Investment Highlights o A leader in respiratory and OSA treatment
More informationInvestor Presentation. Q January 24, 2019
Investor Presentation Q2 2019 January 24, 2019 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results
More informationInvestor Presentation
Investor Presentation Q4 2016 September 9, 2016 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
More informationSleep Disorders and the Metabolic Syndrome
Sleep Disorders and the Metabolic Syndrome Tom V. Cloward, M.D. Intermountain Sleep Disorders Center LDS Hospital Objectives Describe how sleep disorders impact your daily medical practice Don Don t do
More informationCo-Morbidities Associated with OSA
Co-Morbidities Associated with OSA Dr VK Vijayan MD (Med), PhD (Med), DSc, FCCP, FICC, FAPSR, FAMS Advisor to Director General, ICMR Bhopal Memorial Hospital and Research Centre & National Institute for
More informationa new beginning in managing CSA ResMed.com/AirSolutions
a new beginning in managing CSA ResMed.com/AirSolutions As your partner in patient care, ResMed gives you more clinical tools to manage patients with breathing disorders that can sometimes be challenging
More informationThe most accurate predictors of arterial hypertension in patients with Obstructive Sleep Apnea Syndrome
The most accurate predictors of arterial hypertension in patients with Obstructive Sleep Apnea Syndrome Natsios Georgios University Hospital of Larissa, Greece Definitions Obstructive Sleep Apnea (OSA)
More informationSleep Apnea and Heart Failure
Sleep Apnea and Heart Failure Micha T. Maeder, MD Cardiology Division Kantonsspital St. Gallen Switzerland micha.maeder@kssg.ch Sleep Disordered Breathing (SDB) in HFrEF 700 HFrEF patients (LVEF
More informationInvestor Presentation
Investor Presentation Q1 2017 January 5, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
More informationSleep Disordered Breathing: Beware Snoring! Dr T A McDonagh Consultant Cardiologist Royal Brompton Hospital London. UK
Sleep Disordered Breathing: Beware Snoring! Dr T A McDonagh Consultant Cardiologist Royal Brompton Hospital London. UK Sleep Disordered Breathing in CHF Erratic breathing during sleep known for years e.g.
More informationSleep Disordered Breathing
Sleep Disordered Breathing SDB SDB Is an Umbrella Term for Many Disorders characterized by a lack of drive to breathe Results n repetitive pauses in breathing with no effort Occurs for a minimum of 10
More informationPVDOMICS. Sleep Core. Cleveland Clinic Cleveland, Ohio
PVDOMICS Sleep Core Rawan Nawabit, Research Coordinator and Polysomnologist Joan Aylor, Research Coordinator Dr. Reena Mehra, Co-Investigator, Sleep Core Lead Cleveland Clinic Cleveland, Ohio 1 Obstructive
More informationEdoardo Gronda UO cardiologia e Ricerca Dipartimento Cardiovascolare IRCCS MultiMedica
Convegno Pneumologia 2016 Milano 16-18 giugno 2016 Centro Congressi Palazzo delle Stelline Edoardo Gronda UO cardiologia e Ricerca Dipartimento Cardiovascolare IRCCS MultiMedica Central apnea 10 second
More informationObesity, Diabetes and Obstructive Sleep Apnea Syndrome (OSAS ) Jaakko Tuomilehto. Prof. MD, MA, PhD, FRCP (Edin)
Obesity, Diabetes and Obstructive Sleep Apnea Syndrome (OSAS ) Jaakko Tuomilehto Prof. MD, MA, PhD, FRCP (Edin) Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki,
More informationCircadian Variations Influential in Circulatory & Vascular Phenomena
SLEEP & STROKE 1 Circadian Variations Influential in Circulatory & Vascular Phenomena Endocrine secretions Thermo regulations Renal Functions Respiratory control Heart Rhythm Hematologic parameters Immune
More informationReasons Providers Use Bilevel
Reasons Providers Use Bilevel More comfort, improve therapy compliance Noncompliant OSA (NCOSA) 1 Scripts from lab referrals Central/Complex Sleep Apnea 2 For ventilations needs Restrictive Thoracic Disorders/Neuromuscular
More informationTechnology Enabled Management of Sleep Loss as a Strategy to Mitigate the Underlying Cause of Fatigue in Transportation
Technology Enabled Management of Sleep Loss as a Strategy to Mitigate the Underlying Cause of Fatigue in Transportation Jeffrey Durmer, MD, PhD Dr. Jeffrey Durmer Chief Medical Officer, FusionHealth Chief
More informationSleep Quiz & Referral Form Inside
Sleep Quiz & Referral Form Inside Rediscover the power of sleep Apnea solutions for all ages Mobile Sleep Services Who We Are An experienced and well trained team of sleep care professionals consisting
More informationItamar Medical. Investor Presentation August 2018
Itamar Medical Investor Presentation August 2018 Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration
More informationIndex. sleep.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acquired central hypoventilation syndrome, NPPV in children with, 475 Acute cardiogenic pulmonary edema, PAP therapy in, 394 395 Adaptive
More informationBi-Level Therapy: Boosting Comfort & Compliance in Apnea Patients
Bi-Level Therapy: Boosting Comfort & Compliance in Apnea Patients Objectives Describe nocturnal ventilation characteristics that may indicate underlying conditions and benefits of bilevel therapy for specific
More informationMartin R Cowie Professor of Cardiology, National Heart & Lung Institute Imperial College London (Royal Brompton Hospital)
Treatment of Sleep-Disordered Breathing With Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure and Reduced Ejection Fraction (SERVE-HF) Martin R Cowie Professor
More informationComplete Sleep Apnea Care and Diabetes A Study on Total Cost Savings
A Study on Total Cost Savings Our Leadership In Sleep Apnea Care Nevada Sleep Diagnostics, Inc. has a fifteen year history of leadership in sleep apnea care. Nevada Sleep Diagnostics consistently raises
More informationRediscover the power of sleep
Rediscover the power of sleep Patient Copy Apnea solutions for all ages Mobile Sleep Services Who We Are An experienced and well trained team of sleep care professionals consisting of Registered Sleep
More informationManagement of OSA in the Acute Care Environment. Robert S. Campbell, RRT FAARC HRC, Philips Healthcare May, 2018
Management of OSA in the Acute Care Environment Robert S. Campbell, RRT FAARC HRC, Philips Healthcare May, 2018 1 Learning Objectives Upon completion, the participant should be able to: Understand pathology
More informationOventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane
Oventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane February 2018 Twitter: @OventusLtd About Oventus (ASX: OVN) Oventus is commercialising its Airway Technology
More informationMonitoring: gas exchange, poly(somno)graphy or device in-built software?
Monitoring: gas exchange, poly(somno)graphy or device in-built software? Alessandro Amaddeo Noninvasive ventilation and Sleep Unit & Inserm U 955 Necker Hospital, Paris, France Inserm Institut national
More informationDIGITAL AUTO-TRAK + Bi-FLEX + AUTO Bi-LEVEL THE POWER OF. Sometimes when three come together the results can be quite extraordinary. Unique even.
DIGITAL AUTO-TRAK + Bi-FLEX + AUTO Bi-LEVEL THE POWER OF 3 Sometimes when three come together the results can be quite extraordinary. Unique even. W W W. R E S P I R O N I C S. C O M THE BiPAP M SERIES
More informationAre We Sure That Obstructive Sleep Apnea Is Not a Risk factor for Atrial Fibrillation in the Elderly Population?
ISPUB.COM The Internet Journal of Geriatrics and Gerontology Volume 6 Number 1 Are We Sure That Obstructive Sleep Apnea Is Not a Risk factor for Atrial Fibrillation in the Elderly H Ganga, Y Thangaraj,
More informationGoldman Sachs JBWere Australasian Investment Forum New York - 7 March 2006
Goldman Sachs JBWere Australasian Investment Forum New York - 7 March 2006 Investment Highlights Leading player in heated humidification systems Consistent growth strategy Estimated US$2+ billion and growing
More informationResMed 2015 Investor Day. Welcome & Opening Remarks
ResMed 2015 Investor Day Welcome & Opening Remarks Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
More informationAHA Sleep Apnea and Cardiovascular Disease. Slide Set
AHA 2008 Sleep Apnea and Cardiovascular Disease Slide Set Based on the AHA 2008 Scientific Statement Sleep Apnea and Cardiovascular Disease Virend K. Somers, MD, DPhil, FAHA, FACC Mayo Clinic and Mayo
More informationThe Effect of Sleep Disordered Breathing on Cardiovascular Disease
The Effect of Sleep Disordered Breathing on Cardiovascular Disease Juan G. Flores MD Pulmonary, Critical Care and Sleep Medicine Dupage Medical Group Director of Edward Sleep Lab Disclaimers or Conflicts
More informationTreatment of sleep apnea in heart failure patients after SERVE-HF results
Treatment of sleep apnea in heart failure patients after SERVE-HF results Martin R Cowie Professor of Cardiology National Heart & Lung Institute Imperial College London (Royal Brompton Hospital Campus)
More informationA simple solution for your complex patients
A simple solution for your complex patients The market-leading servo ventilation device System One BiPAP autosv Advanced simplifies treating complex sleep-disordered breathing patients Developed for your
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationGOALS. Obstructive Sleep Apnea and Cardiovascular Disease (OVERVIEW) FINANCIAL DISCLOSURE 2/1/2017
Obstructive Sleep Apnea and Cardiovascular Disease (OVERVIEW) 19th Annual Topics in Cardiovascular Care Steven Khov, DO, FAAP Pulmonary Associates of Lancaster, Ltd February 3, 2017 skhov2@lghealth.org
More informationROBERT C. PRITCHARD DIRECTOR MICHAEL O. FOSTER ASSISTANT DIR. SLEEP APNEA
ROBERT C. PRITCHARD DIRECTOR MICHAEL O. FOSTER ASSISTANT DIR. SLEEP APNEA A Person is physically qualified to drive a motor vehicle if that person; -(5) has no established medical history or clinical diagnosis
More informationDear, Respectfully, United Sleep Centers SLEEP STUDY DATE: FEBUARY 26, 2015 AT OUR DOWNEY CENTER TIME: 10PM, PLEASE ARRIVE ON TIME
Sleep Study Instructions SLEEP STUDY DATE: FEBUARY 26, 2015 AT OUR DOWNEY CENTER TIME: 10PM, PLEASE ARRIVE ON TIME ADDRESS: 11411 BROOKSHIRE AVE SUITE 505 DOWNEY, CA Dear, Thank you for choosing us as
More informationItamar Medical. Investors Presentation. June 2016
Itamar Medical Investors Presentation June 2016 Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration
More informationWake up to Life. with ResMed s advanced sleep therapy system.
Wake up to Life with ResMed s advanced sleep therapy system www.s9morecomfort.com A beautiful addition to your lifestyle ResMed s S9 sleep therapy system is proof that superb functionality and contemporary
More informationAsleep at the Wheel Understanding and Preventing Drowsy Driving
LIFESAVERS April 23, 2018 San Antonio, TX 2:15 3:45 PM Room 214 D Sleepiness and Accidents: A Crash Course EVOLVING SAFETY PRIORITIES AND SOLUTIONS Asleep at the Wheel Understanding and Preventing Drowsy
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationSleep Apnea and ifficulty in Extubation. Jean Louis BOURGAIN May 15, 2016
Sleep Apnea and ifficulty in Extubation Jean Louis BOURGAIN May 15, 2016 Introduction Repetitive collapse of the upper airway > sleep fragmentation, > hypoxemia, hypercapnia, > marked variations in intrathoracic
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationSleep Apnea: Diagnosis & Treatment
Disclosure Sleep Apnea: Diagnosis & Treatment Lawrence J. Epstein, MD Sleep HealthCenters Harvard Medical School Chief Medical Officer for Sleep HealthCenters Sleep medicine specialty practice group Consultant
More information(To be filled by the treating physician)
CERTIFICATE OF MEDICAL NECESSITY TO BE ISSUED TO CGHS BENEFICIAREIS BEING PRESCRIBED BILEVEL CONTINUOUS POSITIVE AIRWAY PRESSURE (BI-LEVEL CPAP) / BI-LEVEL VENTILATORY SUPPORT SYSTEM Certification Type
More informationGlobal Continuous Positive Airway Pressure(CPAP) Devices Market Research Report - Forecast to 2027
Report Information More information from: https://www.marketresearchfuture.com/reports/939 Global Continuous Positive Airway Pressure(CPAP) Devices Market Research Report - Forecast to 2027 Report / Search
More informationUpdate on Sleep Apnea Diagnosis and Treatment
Update on Sleep Apnea Diagnosis and Treatment Damien Stevens MD Pulmonary/Critical Care/Sleep Medicine Medical Director KU Medical Center Sleep Laboratory Objectives Discuss physiology of sleep and obstructive
More informationNON-INVASIVE VENTILATION MADE RIDICULOUSLY SIMPLE
NON-INVASIVE VENTILATION MADE RIDICULOUSLY SIMPLE Jennifer Newitt, MD 3 rd year Pulmonary/Critical Care Fellow Mentor: Patrick Strollo Jr, MD Myth or Fact?!? Myth or Fact?!? Treatment for Obstructive
More informationIndex. sleep.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Accidents. See Motor vehicle accidents. Acetazolamide, in OSA therapy, 531 Acetylcholinesterase inhibitors, in OSA therapy, 532 533 Acromegaly,
More informationAll About Positive Airway Pressure (PAP) Therapy
All About Positive Airway Pressure (PAP) Therapy Nitipatana Chierakul Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Medical School Siriraj Sleep Center: Fiscal-year
More informationCase. Case. Case. Sleep Disorders: A Case-based Approach. LeRoy Essig, MD Rami Khayat, MD ROS:
Sleep Disorders: A Case-based Approach LeRoy Essig, MD Rami Khayat, MD Case ROS: 30 Lbs wt gain/1year Fatigue Heart burn Nasal congestion, dry mouth Reduced concentration/memory Case 47 y/o male presents
More informationFor personal use only
ASX Release Oventus presentation for AGM of Thorney Technologies Ltd Brisbane, Australia 24 th November 2017: Oventus Medical Ltd (ASX: OVN) is pleased to release a copy of the presentation that Founder
More informationIs CPAP helpful in severe Asthma?
Is CPAP helpful in severe Asthma? P RAP UN KI TTIVORAVITKUL, M.D. PULMONARY AND CRITICAL CARE DIVISION DEPARTMENT OF MEDICINE, PHRAMONGKUTKLAO HOSPITAL Outlines o Obstructive sleep apnea syndrome (OSAS)
More information11/13/2017. Jeremy Tabak MD, FAASM Medical Director Baptist Hospital Sleep Lab Medical Director Baptist Sleep Lab at Galloway
Jeremy Tabak MD, FAASM Medical Director Baptist Hospital Sleep Lab Medical Director Baptist Sleep Lab at Galloway HypnoLaus study: OSA effect on mortality US Preventive Services Task Force recommendations
More informationRESEARCH PACKET DENTAL SLEEP MEDICINE
RESEARCH PACKET DENTAL SLEEP MEDICINE American Academy of Dental Sleep Medicine Dental Sleep Medicine Research Packet Page 1 Table of Contents Research: Oral Appliance Therapy vs. Continuous Positive Airway
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationRest Stop #101. Sleep & Fatigue-What s the difference and what to do about it.
Rest Stop #101 This Photo by Unknown Author is licensed under CC BY-NC-ND Sleep & Fatigue-What s the difference and what to do about it. Presented by Mary Convey, Director of Key Accounts & Risk Mitigation
More informationPolicy Specific Section: October 1, 2010 January 21, 2013
Medical Policy Bi-level Positive Airway Pressure (BPAP/NPPV) Type: Medical Necessity/Not Medical Necessity Policy Specific Section: Durable Medical Equipment Original Policy Date: Effective Date: October
More informationBest Match. Non-Invasive Ventilation. WSS Fall Objectives. BiPAP AVAPS Patient Types 9/10/2018. Advanced Algorithms - Clinical Applications
WSS Fall 2018 Advanced Algorithms - Clinical Applications Average Volume Assured Ventilation (AVAPS) Auto Servo Ventilation (SV) Hank Hart BS, LPN Objectives Differentiate between BiPAP AVAPS and BiPAP
More informationMario Kinsella MD FAASM 10/5/2016
Mario Kinsella MD FAASM 10/5/2016 Repetitive episodes of apnea or reduced airflow Due to upper airway obstruction during sleep Patients often obese Often have hypertension or DM 1 Obstructive apneas, hypopneas,
More information